Recombinant
            <i>Leishmania Tarentolae</i>
            Encoding the HPV Type 16
            <i>E7</i>
            gene in Tumor Mice Model

Salehi, Maryam; Taheri, Tahereh; Mohit, Elham; Zahedifard, Farnaz; Seyed, Negar; Taslimi, Yasaman; Sattari, Mandana; Bolhassani, Azam; Rafati, Sima

doi:10.2217/imt.12.110

Cited by 28 publications

(23 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recombinant L. tarentolae expressing HIV-1 Gag protein induced strong cell-mediated immunity in mice and decreased HIV-1 replication in an ex vivo system, suggesting that this species can be applied as a promising live vaccine against intracellular pathogens [10]. Recently, a recombinant L. tarentolae strain expressing HPV-E7 antigen-green fluorescent protein (GFP) was developed and showed a potential as a live vaccine against HPV infection [36]. Additionally, modification of, and insertion into, the genome of L. tarentolae can be done easily and there is no insert size limitation making it a versatile tool for vaccine development.…”

Section: Discussionmentioning

confidence: 99%

Enhanced Protective Efficacy of Nonpathogenic Recombinant Leishmania tarentolae Expressing Cysteine Proteinases Combined with a Sand Fly Salivary Antigen

et al. 2014

Self Cite

View full text Add to dashboard Cite

BackgroundNovel vaccination approaches are needed to prevent leishmaniasis. Live attenuated vaccines are the gold standard for protection against intracellular pathogens such as Leishmania and there have been new developments in this field. The nonpathogenic to humans lizard protozoan parasite, Leishmania (L) tarentolae, has been used effectively as a vaccine platform against visceral leishmaniasis in experimental animal models. Correspondingly, pre-exposure to sand fly saliva or immunization with a salivary protein has been shown to protect mice against cutaneous leishmaniasis.Methodology/Principal FindingsHere, we tested the efficacy of a novel combination of established protective parasite antigens expressed by L. tarentolae together with a sand fly salivary antigen as a vaccine strategy against L. major infection. The immunogenicity and protective efficacy of different DNA/Live and Live/Live prime-boost vaccination modalities with live recombinant L. tarentolae stably expressing cysteine proteinases (type I and II, CPA/CPB) and PpSP15, an immunogenic salivary protein from Phlebotomus papatasi, a natural vector of L. major, were tested both in susceptible BALB/c and resistant C57BL/6 mice. Both humoral and cellular immune responses were assessed before challenge and at 3 and 10 weeks after Leishmania infection. In both strains of mice, the strongest protective effect was observed when priming with PpSP15 DNA and boosting with PpSP15 DNA and live recombinant L. tarentolae stably expressing cysteine proteinase genes.Conclusion/SignificanceThe present study is the first to use a combination of recombinant L. tarentolae with a sand fly salivary antigen (PpSP15) and represents a novel promising vaccination approach against leishmaniasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Enhanced Protective Efficacy of Nonpathogenic Recombinant Leishmania tarentolae Expressing Cysteine Proteinases Combined with a Sand Fly Salivary Antigen

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…Its higher sensitivity to CIN screening may become a major tool to screen cervical cancer in women over 30 years old. HPV virus can not be cultivated in vitro, and the immunoreactions easy to detect can also not be induced in vivo (Salehi et al, 2012), so its diagnosis and classification are not be detected with serological test. In recent years, a lot of literatures revealed that persistent HPV infection is a high-risk factor of cervical cancer, especially highrisk HPV infection which is one of the causes that result in the high-grade lesion of cervical cancer and CIN.…”

Section: Discussionmentioning

confidence: 99%

Application of Human Papillomavirus in Screening for Cervical Cancer and Precancerous Lesions

Wang

Yang²,

Dong³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Currently, we showed that a recombinant L. tarentolae strain expressing high levels of full-length HPV16 E7 was immunogenic and could induce the production of IFN-g cytokine. Furthermore, the protective effects of both subcutaneously DNA and live vaccine strategies were similar in tumor mice model (Salehi et al, 2012). These data indicated that further studies are required to increase live vaccine efficacy using different potent components such as adjuvants.…”

Section: Introductionmentioning

confidence: 72%

A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers

et al. 2013

Self Cite

View full text Add to dashboard Cite

The attenuated or non-pathogenic live vectors have been evolved specifically to deliver DNA into cells as efficient delivery tools in gene therapy. Recently, a non-pathogenic protozoan, Leishmania tarentolae (L.tar) has attracted a great attention. In current study, we used Leishmania expression system (LEXSY) for stable expression of HPV16 E7 linked to different mini-chaperones [N-/C-terminal of gp96] and compared their immunogenicity and protective effects in C57BL/6 mice against TC-1 challenge. TC-1 murine model is primary C57BL/6 mice lung epithelial cells co-transformed with HPV16 E6, HPV16 E7 and ras oncogenes. Our results showed that subcutaneous administration of mice with both the recombinant L.tar-E7-NT

show abstract

Recombinant Leishmania Tarentolae Encoding the HPV Type 16 E7 gene in Tumor Mice Model

Abstract: Overall, the results obtained revealed that the E7-GFP recombinant L. tarentolae could be a potential live vaccine for induction of immune responses in vivo.

Cited by 28 publications

References 62 publications

Enhanced Protective Efficacy of Nonpathogenic Recombinant Leishmania tarentolae Expressing Cysteine Proteinases Combined with a Sand Fly Salivary Antigen

Enhanced Protective Efficacy of Nonpathogenic Recombinant Leishmania tarentolae Expressing Cysteine Proteinases Combined with a Sand Fly Salivary Antigen

Application of Human Papillomavirus in Screening for Cervical Cancer and Precancerous Lesions

A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers

Contact Info

Product

Resources

About